Velaglucerase alfa

All Wales Medicines Strategy Group (AWMSG)

Record ID 32014001439

English

Authors' recommendations: Velaglucerase alfa (VPRIV®) is recommended as an option for use within NHS Wales for long-term enzyme replacement therapy in patients with type 1 Gaucher disease. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.

Details

Project Status: Completed

Year Published: 2014

URL for published report: http://www.awmsg.org/awmsgonline/app/appraisalinfo/571

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Wales, United Kingdom

MeSH Terms

Gaucher Disease
Glucosylceramidase

Contact

Organisation Name: All Wales Medicines Strategy Group

Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX

Contact Name: AWTTC@wales.nhs.uk

Contact Email: AWTTC@wales.nhs.uk

Copyright: AWTTC

This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.